Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...

Daratumumab plus VRd and frontline daratumumab plus VTd produced deep, durable responses in patients with transplant-eligible multiple myeloma in updates to the PERSEUS and CASSIOPEIA trials ...

Janssen-Cilag’s Darzalex -SC based quadruplet regimen gets European approval to treat patients with newly diagnosed MM who are transplant-eligible: Beerse, Belgium Thursday, Oct ...

In the treatment of patients with newly diagnosed multiple myeloma (MM) who are not eligible for stem cell transplant or are transplant-deferred, adding subcutaneous daratumumab to bortezomib ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for ...

Blood cancer patients in their 40s and 50s are urging Pharmac to overhaul its funding model, saying they have potentially years of work and paying tax ahead of them.

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab for patients with newly diagnosed multiple myeloma. Patients newly ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the safety data from the phase 3 CEPHEUS trial in newly diagnosed multiple ...

RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual ...

Seltorexant is one of J&J’s most promising neuroscience candidates. The human orexin-2 receptor selective agonist produced ...

Company AnnouncementNet sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 millionGenmab receives royalties on worldwide net sales ...

Daratumumab, hyaluronidase-fihj; 1800mg/30000units; per vial; soln for SC inj; preservative-free. Daratumumab binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing ...